Table 1.
Overview of the clinical data of patients analyzed for CETC without and with trastuzumab treatment
| Total | Patients treated without trastuzumab | Patients treated with trastuzumab | P | Primarily metastsized patients | |
|---|---|---|---|---|---|
| 79 (100%) | 35 (44%) | 36 (46%) | 8 (10%) | ||
| HR positive | 55 (70%) | 23 (66%) | 26 (72%) | 0.434 | 6 (75%) |
| HR negative | 23 (29%) | 12 (34%) | 9 (25%) | 2 (25%) | |
| NA | 1 (1%) | 0 (0%) | 1 (3%) | 0 (0%) | |
| Age | 58 | 60 | 55 | 60 | |
| HER2/neu-positive | 74 (94%) | 33 (94%) | 35 (97%) | 0.307 | 6 (75%) |
| HER2/neu negative | 3 (4%) | 1 (3%) | 0 (0%) | 2 (25%) | |
| NA | 2 (2%) | 1 (3%) | 1 (3%) | 0 (0%) | |
| Tumor status T1 | 48 (61%) | 22 (63%) | 22 (61%) | 4 (50%) | |
| Tumor status T > 1 | 28 (35%) | 11 (31%) | 13 (36%) | 4 (50%) | |
| NA | 3 (4%) | 2 (6%) | 1 (3%) | ||
| Lymph node status N0 | 42 (53%) | 19 (54%) | 20 (55%) | 0.916 | 3 (37%) |
| Lymph node status N1 | 35 (45%) | 15 (43%) | 15 (42%) | 5 (63%) | |
| NA | 2 (2%) | 1 (3%) | 1 (3%) | 0 (0%) | |
| CR | 54 (68%) | 20 (57%) | 31 (86%) | 3 (37%) | |
| Relapse | 25 (32%) | 15 (43%) | 5 (14%) | 0.007 | 5 (63%) |
| CETC | |||||
| Decrease | 46 (58%) | 19 (54%) | 25 (69%) | 2 (25%) | |
| Increase | 26 (33%) | 9 (26%) | 11 (31%) | 6 (75%) | |
| NA | 7 (9%) | 7 (20%) | 0 (0%) | 0 (0%) | |
HR hormone receptor, CR complete remission, NA not analyzed